B-cell prolymphocytic leukemia with TP53 deletion or mutation

Clinical scenario

TP53 deletion / mutation

B-cell prolymphocytic leukemia (B-PLL) presenting with deletion or mutation of TP53 defines a high-risk subgroup. This genetic abnormality has direct implications for treatment selection, as standard chemo-immunotherapy regimens designed for patients with intact TP53 function are not the preferred approach here.

For patients with nonfunctional TP53, the treatment strategy departs meaningfully from the standard pathway — alternative agents have historically formed the mainstay of management in this setting.

Treatment approach (partial overview)

For B-PLL with TP53 deletion or mutation, the protocol addresses this high-risk genetic context with targeted options — including a BCR pathway inhibitor — alongside consideration of other specialised therapies. The full algorithm specifies agent selection, sequencing criteria, and escalation options.

Full regimen details, sequencing, and criteria available in the structured protocol →

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1182/asheducation-2015.1.361

For T-PLL, first-line therapy is with intravenous alemtuzumab and for B-PLL is with combination chemo-immunotherapy for patients with normal TP53 and with alemtuzumab or BCR inhibitors for those with deletions or mutations of TP53.

For those patients with nonfunctional TP53, alemtuzumab has historically been the mainstay of treatment and, although no longer licensed in CLL, is available via a patient access scheme.

In B-PLL, depending on the remission duration after first-line treatment, relapse can be managed with the same or similar chemo-immunotherapy regimens.

Patients with early relapse or that were associated with high-risk genetics (eg, abnormal TP53) may be considered for treatment with novel BCR inhibitors, such as ibrutinib or idelalisib, or other experimental therapies, preferably within a clinical trial setting.

View source ↗